secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2026-08-10T12:00:16+00:00
Accession:  0001193125-26-341300
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Q2 revenue $37.7M (+1.3% YoY); withdraws FY2026 guidance on CINVANTI patent loss
--------------------------------------------------------------------------------

- Q2 net revenue $37.7M, up 1.3% YoY; Acute Care up 43.9%, Oncology down 15.9% (CINVANTI -9.7%, SUSTOL -77.5%).
- Withdrew FY2026 guidance after Delaware court ruling on CINVANTI patents; paused sales force expansion, considering strategic alternatives.
- Amended Hercules Capital credit facility: $13.5M principal reduction at execution, potential $4M more by Sept 15, 2026; covenants reset through 2027.
- Cash and investments $42.7M at quarter end; ZYNRELEF net revenue $11.1M (+35% YoY), APONVIE $4.2M (+74% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/0001193125-26-341300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/hrtx-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer